VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Status:
Recruiting
Trial end date:
2025-04-22
Target enrollment:
Participant gender:
Summary
This is a prospective single arm, multi-center, phase II clinical trial to observe the
efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and
Prednisone) in the first-line treatment for patients with marginal zone lymphoma.